Abstract:The present study aimed to verify the impact of etiological treatment on the genotype-specific serological diagnosis of chronic Chagas disease patients (CH), using the Chagas-Flow ATE IgG1 methodology. For this purpose, a total of 92 serum samples from CH, categorized as Not Treated (NT, n = 32) and Benznidazole-Treated (Bz-T, n = 60), were tested at Study Baseline and 5 Years Follow-up. At Study Baseline, all patients have the diagnosis of Chagas disease confirmed by Chagas-Flow ATE IgG1, using the set of attributes ("antigen/serum dilution/cut-off"; "EVI/250/30%"). The genotype-specific serodiagnosis at Study Baseline demonstrated that 96% of patients (44/46) presented a serological profile compatible with TcII genotype infection. At 5 Years Follow-up monitoring, NT and Bz-T presented no changes in anti-EVI IgG1 reactivity. However, significant differences were detected in the genotype-specific IgG1 reactivity for Bz-T. The most outstanding shift comprised the anti-amastigote TcVI/(AVI), anti-amastigote TcII/(AII) and anti-epimastigote TcVI/(EVI) reactivities. Regardless no changes in the genotype-specific serology of NT (TcI = 6%; TcII = 94%), distinct T . cruzi genotype-specific sero-classification was detected for Bz-T samples at 5 Years Follow-up (TcII = 100%) as compared to Baseline (TcII = 97%; TcVI = 3%). The anti-trypomastigote TcI/(TI) was the attribute accountable for the change in genotype-specific sero-classification. In conclusion, our findings of dissimilar T . cruzi genotype-specific serology upon Bz-treatment re-emphasize the relevance of accomplishing the genotype-specific serodiagnosis during clinical pos-therapeutic management of chronic Chagas disease patients. Chagas disease is still a serious public health problem worldwide. Currently, only two drugs are available for the treatment of patients infected by T . cruzi : Benzonidazole and Nifurtimox. The efficacy of these compounds may differ depending on the phase of the disease when the treatment is established and also impacted by the T . cruzi genotypes that cause the infection. Thus, differences in therapeutic efficacy can be observed between geographic areas due to the distinct distribution of " Discrete Typing Unitys " (DTUs) of T . cruzi . Besides all these matters related to the etiological treatment, additional concerns regarding the laboratorial methods available for post-therapeutic monitoring of Chagas disease represent a challenge during clinical management. Amongst the innovative serological approaches, proposed for diagnosis and post-therapeutic monitoring of Chagas disease, the Chagas-Flow ATE IgG1 has been presented as an outstanding methodology, applicable for universal and genotype-specific serology. In the present study, the Chagas-Flow ATE IgG1 methodology was used for post-therapeutic monitoring of chronic Chagas disease patients, aiming at identifying changes in T . cruzi genotype-specific serological profile upon Benznidazole etiological treatment. This approach is relevant to provide novel insights to support the relevance of accomplishing the genotype-specific serodiagnosis during clinical pos-therapeutic management of chronic Chagas disease patients.

Molecular detection and parasite load of Trypanosoma cruzi in digestive tract tissue of Chagas disease patients affected by megacolon.

Microbiome Alterations Driven by Trypanosoma cruzi Infection in Two Disjunctive Murine Models

Parasite Burden of Trypanosoma cruzi in Whole Blood and Buffy Coat Determined by Real-Time PCR in Individuals with Chronic Chagas Disease

Transcriptomic evidence of immune modulation in subjects with chronic Trypanosoma cruzi infection

Serial ‘deep-sampling’ PCR of fragmented DNA reveals the wide range of Trypanosoma cruzi burden among chronically infected hosts and allows accurate monitoring of parasite load following treatment

Characterization of Latin American migrants at risk for Trypanosoma cruzi infection in a non-endemic setting. Insights into initial evaluation of cardiac and digestive involvement

Characterization of Novel Trypanosoma cruzi-Specific Antigen with Potential Use in the Diagnosis of Chagas Disease

Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease

Comparison of the Bacterial Gut Microbiome of North American Triatoma spp. With and Without Trypanosoma cruzi

New insights into Trypanosoma cruzi genetic diversity, and its influence on parasite biology and clinical outcomes

Loop-Mediated Isothermal Amplification of Trypanosoma cruzi DNA for Point-of-Care Follow-Up of Anti-Parasitic Treatment of Chagas Disease

Quantitative Proteomic Analysis of Macrophages Infected with Trypanosoma cruzi Reveals Different Responses Dependent on the SLAMF1 Receptor and the Parasite Strain

Trypanosoma cruzi infection follow-up in a sylvatic vector of Chagas disease: Comparing early and late stage nymphs

Impact of gastrointestinal inoculation and benznidazole treatment on infection by Trypanosoma cruzi (Y strain, DTU TcII) in Swiss mice

Association between altered tryptophan metabolism, plasma aryl hydrocarbon receptor agonists, and inflammatory Chagas disease

Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy

A panel of phenotypically and genotypically diverse bioluminescent:fluorescent Trypanosoma cruzi strains as a resource for Chagas disease research

Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease

Humans seropositive for Trypanosoma cruzi co-infected with intestinal helminths have higher infectiousness, parasitaemia and Th2-type response in the Argentine Chaco

Trypanosoma Cruzi Infection Induces a Global Host Cell Response in Cardiomyocytes